• Alias: RG7221; RO5520985
    • An antiangiogenic, first-in-class, bispecific mAb targeting VEGF-A and angiopoietin-2 (Ang-2)
    • Phase 2 in combination with FOLFOX versus FOLFOX + Bevacizumab in untreated, mCRC
    • Recommended dose: 2,000 mg IV every 2 weeks in combination with chemotherapy
    • Half-life: 6 to 9 days
    • Common side effects: Hypertension, asthenia, headache, hemorrhage, thrombosis
    (Hidalgo et al., 2018)
    Other topics in Targeted and Immunotherapy Agents